ACHILLION PHARMACEUTICALS INC - FORM 10-K - EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 906 - March 11, 2010

Attached files

file filename
10-K - FORM 10-K - ACHILLION PHARMACEUTICALS INCd10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - ACHILLION PHARMACEUTICALS INCdex312.htm
EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - ACHILLION PHARMACEUTICALS INCdex231.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - ACHILLION PHARMACEUTICALS INCdex311.htm
EX-10.5 - AMENDED AND RESTATED LICENSE AGREEMENT - ACHILLION PHARMACEUTICALS INCdex105.htm
EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 906 - ACHILLION PHARMACEUTICALS INCdex321.htm
EX-10.26 - 2006 STOCK INCENTIVE PLAN AS AMENDED SEPTEMBER 18, 2006 AND MARCH 9, 2010 - ACHILLION PHARMACEUTICALS INCdex1026.htm
EX-10.10 - SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT - MILIND DESPHANDE - ACHILLION PHARMACEUTICALS INCdex1010.htm
EX-10.12 - SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT - MARY KAY FENTON - ACHILLION PHARMACEUTICALS INCdex1012.htm
EX-10.32 - 2006 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED SEPTEMBER 18, 2006 - ACHILLION PHARMACEUTICALS INCdex1032.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report on Form 10-K of Achillion Pharmaceuticals, Inc. (the “Company”) for the period ended December 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Mary Kay Fenton, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350 as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 11, 2010

/s/    MARY KAY FENTON        

Mary Kay Fenton
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Achillion Pharmaceuticals, Inc. and will be retained by Achillion Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

ACHILLION PHARMACEUTICALS INC Reports